Furthermore, inhibitors of AGE-RAGE axis like DPP-IV inhibitors (sitagliptin) have also been tested in other impaired metabolic conditions like type-2 diabetes to possibly work as a cancer-protective agent in diabetes by disrupting the AGE-RAGE cues [131]. This evidence concerns the gene AGER and type 2 diabetes mellitus.